Although psoriasis remains one of the most devastating inflammatory disorders due to its huge negative impact on patients’ quality of life, new “green” treatment approaches still need to be fully explored. The purpose of this review article is to focus on the utilization of different essential oils and active constituents of herbal botanical origin for the treatment of psoriasis that proved efficacious via both in vitro and in vivo models. The applications of nanotechnology-based formulations which displayed great potential in augmenting the permeation and delivery of these agents is also addressed. Numerous studies have been found which assessed the potential activity of natural botanical agents to overcome psoriasis. Nano-architecture delivery is applied in order to maximize the benefits of their activity, improve properties, and increase patient compliance. This field of natural innovative formulations can be a promising tool to optimize remediation of psoriasis while minimizing adverse effects.
15 June 2024 in Eastern Mediterranean Health Journal
Background: Genetic data transfer within multicentre clinical trials conducted in low- and middle-income countries is common and must be communicated to study participants as part of ethical requirements. Aims: To analyse ethics practices in precision medicine research in low- and middle-income countries and make useful recommendations. Methods: We conducted a narrative review of published literature and existing ethics frameworks regarding underrepresentation of low- and middle-income countries in genomic databases, informed consent and data security discussions, as well as the potential for exploitation and limited access to benefits. Results: The findings highlight the need for increased diversity in research participation, robust ethical frameworks, and knowledge sharing between developed and developing countries. The findings show that strengthening national research ethics committees and fostering collaboration can help low- and middle-income countries in addressing unique challenges and harnessing the potential of precision medicine while ensuring ethical conduct and equitable access for all. Our review emphasizes the importance of ethical considerations in precision medicine research to ensure that its benefits reach all affected populations, promoting a more just and more equitable healthcare future. Conclusion: There is a need to ensure that research participants are accorded the rights, whether in the ownership of their samples or the right to know what type of genetic studies have been conducted on their samples. It is important to have binding agreements that will allow clinical trial participants to access drugs that proof effective based on the trials they participated in.
Purpose: This study aimed to enhance the therapeutic effect of fluticasone (FP) for psoriasis using black cumin oil-based nanostructured lipid carriers (NLCs) with dual deposition/permeation capabilities to achieve high drug localization within the viable skin layers (deposition) for targeted topical action, while concurrently facilitating efficient drug flux through the skin (permeation) to address the full depth of psoriatic plaques. Methods: Oil selection followed a preliminary NLC optimization study. Characterization used microscopy, FTIR, DSC, ex vivo skin permeation and deposition, and in vivo pharmacodynamics with imiquimod-induced psoriatic mice. Results: The optimized NLC showed a size of 171.3 nm, a PDI of 0.37, and a zeta potential of -32.3 mV. Ex-vivo data showed dual local/systemic distribution, with FP deposition in the stratum corneum and epidermis, plus superior permeation versus marketed cream. An in vivo study revealed PASI score improvement up to 77%. IL-6 and IL-1α levels were significantly reduced. Histology showed inflammation decline. Conclusion: Results demonstrated improved anti-psoriatic action using the dual distribution/combinatorial approach with the optimized formulation. The data confirmed that the black cumin oil-based NLC formulation offers better outcomes than the standard cream by enhancing FP skin targeting, penetration, and anti-inflammatory response in psoriatic models.
18 August 2025 in International Journal of Pharmaceutics: X
Tadalafil (TDLF), a Biopharmaceutics Classification System (BCS) Class II drug, exhibits poor aqueous solubility and extensive first-pass metabolism, which limits its therapeutic efficacy. We developed Phosal-based transethosomes (TrEthOs) to overcome these challenges, thereby enhancing transdermal delivery. A Box-Behnken design was employed to optimize the formulation by evaluating the effects of Phosal type, polyethylene glycol (PEG) 400 concentration, and cholesterol content. The optimized TrEthOs exhibited a mean vesicle size of 129.74 nm and an entrapment efficiency of 67.3%, ensuring efficient encapsulation of the drug. Ex vivo permeation studies demonstrated a cumulative TDLF permeation of 70.24% over 6 hours, with a steady-state flux of 19.49 × 10-4 mg/cm2·min. Confocal laser scanning microscopy confirmed deep skin penetration, while in vitro studies revealed significantly enhanced cellular uptake (P < 0.0001) and reduced cytotoxicity (IC₅₀ = 67.61 μg/mL) compared to pure TDLF (IC₅₀ = 34.85 μg/mL). The novel Phosal-based TrEthOs system presents a promising transdermal drug delivery strategy, potentially reducing dosing frequency and improving patient compliance. These outcomes emphasize the potential of advanced nanocarrier systems to optimize systemic bioavailability while minimizing adverse effects.